Literature DB >> 20595287

Improving the routine management of rheumatoid arthritis: the value of tight control.

Philip J Mease1.   

Abstract

Evidence is mounting that adopting a tight control approach to the management of patients with rheumatoid arthritis (RA) yields superior clinical outcomes including inhibition of progressive structural damage. While this approach has been successfully implemented in other chronic diseases, such as diabetes, its use in RA is less straightforward as there is not a simple "gold standard" measure for disease activity. A key component of the tight control approach is the availability of easily implemented and clinically relevant assessment measures of disease activity that allow physicians to monitor progress toward preset goals. This article summarizes the evidence from clinical trials demonstrating the benefits of achieving tight control and surveys the instruments available to assess patient progress in a consistent manner. A case study clearly demonstrates the benefits of the tight control approach in routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20595287     DOI: 10.3899/jrheum.091064

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Subjective numeracy and preference to stay with the status quo.

Authors:  Liana Fraenkel; Meaghan Cunningham; Ellen Peters
Journal:  Med Decis Making       Date:  2014-04-23       Impact factor: 2.583

2.  [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Authors:  K Krüger; J Wollenhaupt; K Albrecht; R Alten; M Backhaus; C Baerwald; W Bolten; J Braun; H Burkhardt; G Burmester; M Gaubitz; A Gause; E Gromnica-Ihle; H Kellner; J Kuipers; A Krause; H-M Lorenz; B Manger; H Nüßlein; H-G Pott; A Rubbert-Roth; M Schneider; C Specker; H Schulze-Koops; H-P Tony; S Wassenberg; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

Review 3.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

4.  High disease activity may not be sufficient to escalate care.

Authors:  Liana Fraenkel; Meaghan Cunningham
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-02       Impact factor: 4.794

5.  Designation of a novel DKK1 multiepitope DNA vaccine and inhibition of bone loss in collagen-induced arthritic mice.

Authors:  Xiaoqing Zhang; Sibo Liu; Shentao Li; Yuxuan Du; Yunpeng Dou; Zhanguo Li; Huihui Yuan; Wenming Zhao
Journal:  Biomed Res Int       Date:  2015-05-05       Impact factor: 3.411

6.  Importance of Shared Treatment Goal Discussions in Rheumatoid Arthritis-A Cross-Sectional Survey: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed.

Authors:  Kelly D O'Neill; Kathryne E Marks; Pamela S Sinicrope; Cynthia S Crowson; Dana Symons; Elena Myasoedova; John M Davis
Journal:  ACR Open Rheumatol       Date:  2021-09-18

7.  Development of a multi-biomarker disease activity test for rheumatoid arthritis.

Authors:  Michael Centola; Guy Cavet; Yijing Shen; Saroja Ramanujan; Nicholas Knowlton; Kathryn A Swan; Mary Turner; Chris Sutton; Dustin R Smith; Douglas J Haney; David Chernoff; Lyndal K Hesterberg; John P Carulli; Peter C Taylor; Nancy A Shadick; Michael E Weinblatt; Jeffrey R Curtis
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

8.  Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.

Authors:  Aatke van der Maas; Bart J F van den Bemt; Gertjan Wolbink; Frank H J van den Hoogen; Piet L C M van Riel; Alfons A den Broeder
Journal:  BMC Musculoskelet Disord       Date:  2012-09-24       Impact factor: 2.362

Review 9.  S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis.

Authors:  Kwi Young Kang; Jung-Won Woo; Sung-Hwan Park
Journal:  Korean J Intern Med       Date:  2014-01-02       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.